EXAS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EXAS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Exact Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $326 Mil. Exact Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2,229 Mil. Exact Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $3,133 Mil. Exact Sciences's debt to equity for the quarter that ended in Mar. 2024 was 0.82.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Exact Sciences's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Exact Sciences was 1.09. The lowest was 0.01. And the median was 0.68.
The historical data trend for Exact Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial |
![]() |
![]() |
0.42 | 1.04 | 0.70 | 0.80 | 0.81 |
Exact Sciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-Equity | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.84 | 0.84 | 0.82 | 0.81 | 0.82 |
For the Diagnostics & Research subindustry, Exact Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Exact Sciences's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Exact Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (79.379 | + | 2475.346) | / | 3145.305 | |
= | 0.81 |
Exact Sciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (326.035 | + | 2229.21) | / | 3132.618 | |
= | 0.82 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Sciences (NAS:EXAS) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Exact Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Baranick | officer: Gen. Mgr., Precision Oncology | 441 CHARMANY DRIVE, MADISON WI 53719 |
Sarah Condella | officer: SVP, Human Resources | 441 CHARMANY DRIVE, MADISON WI 53719 |
Timothy J Scannell | director | 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002 |
Everett Cunningham | officer: Chief Commercial Officer | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Jeffrey Thomas Elliott | officer: Chief Financial Officer | 5505 ENDEAVOR LANE, MADISON WI 53719 |
James Edward Doyle | director | 5505 ENDEAVOR LANE, MADISON WI 53719 |
James Herriott | officer: General Counsel | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Katherine S Zanotti | director | 431 E 9TH STREET, HINSDALE IL 60521 |
Jacob A Orville | officer: General Manager, New Ventures | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Kevin T Conroy | director, officer: Vice President | 5505 ENDEAVOR LANE, MADISON WI 53719 |
D Scott Coward | officer: SVP and General Counsel | 441 CHARMANY DRIVE, MADISON WI 53719 |
Paul J Clancy | director | C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Graham Peter Lidgard | officer: SVP, Chief Scientific Officer | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Michael S Wyzga | director | RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139 |
Torsten Hoof | officer: General Manager, International | 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
From GuruFocus
By PRNewswire PRNewswire • 05-09-2023
By PRNewswire PRNewswire • 06-20-2023
By GuruFocus Research • 11-02-2023
By PRNewswire PRNewswire • 06-21-2023
By PRNewswire • 08-01-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire • 10-22-2023
By PRNewswire PRNewswire • 05-17-2023
By GuruFocus Research • 11-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.